Press Releases
NRx Pharmaceuticals (NASDAQ:NRXP) Announces Publication of Paper Entitled “Quality Assurance of Depression Ratings in Psychiatric Clinical Trials”
NRx-developed training and monitoring methodology in recently completed phase 2b/3 clinical trial of NRX-101 documents higher interrater reliability (IRR) on primary endpoint (MADRS depression scale) than previously reported industry standardsPositive
